| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 13.55 | 13.38 |
| Pretax Income | 1.47 | 0.30 |
| Net Income | -0.12 | 0.86 |
| Diluted EPS | -0.01 | 0.06 |
- Net Income YoY
- -113.7%
Key highlights
- Revenue reached $13.55 million, up from $13.38 million in the prior year's third quarter
- Net income decreased 113.7% year-over-year to a loss of $0.12 million
- Pretax income improved significantly to $1.47 million from $0.30 million in Q3 2025
- Total assets declined to $40.7 million from $61.0 million at year-end 2025
- Full-year 2026 system-wide sales guidance updated to between $508 million and $512 million
How the Period Went
The Joint Corp’s top-line performance remained steady during the third quarter of 2026, with revenue reaching $13.55 million, a slight increase from $13.38 million in the same period last year. However, the bottom line experienced pressure as net income dropped by 113.7% to a loss of $0.12 million. This contrasted with the $0.86 million profit recorded in Q3 2025. Diluted earnings per share shifted from $0.06 to -$0.01. Despite the net loss, the company saw a rise in pretax income, which climbed to $1.47 million from $0.30 million, suggesting that the primary earnings drag originated from discontinued operations or non-operating adjustments.
Margins and Profitability
Profitability in the quarter was largely influenced by the company's transition away from corporate-owned clinic management. While pretax income saw a five-fold increase to $1.47 million, the net loss reflects the costs associated with the ongoing refranchising strategy. A major driver of balance sheet contraction was the reduction in assets related to discontinued operations, which fell from $61.0 million at the end of 2025 to $40.7 million as of September 30, 2026. This shift aims to optimize the capital structure by moving toward a higher-margin franchise-fee model, even if it creates short-term volatility in reported net earnings.
Business Overview
The Joint Corp operates as a leading franchisor and operator of chiropractic clinics across the United States. Its business model centers on providing accessible, no-appointment-needed chiropractic care through a private-pay system, bypassing traditional insurance complexities. The company earns revenue through royalty fees from franchisees, marketing fund contributions, and the operation of a diminishing pool of company-owned clinics. By focusing on the domestic chiropractic market, The Joint serves a broad consumer base seeking routine wellness and pain management in a retail-like environment. The company currently manages a $0 backlog, consistent with its walk-in clinic business model.
Financial Context
The Joint Corp’s current valuation reflects its transitional phase, with a P/E ratio of 52.6x and a market capitalization of approximately $100.9 million. The stock has faced some recent headwinds, evidenced by a -10.99% decline over the last quarter, though it has stabilized recently with an RSI of 49.9. While quarterly revenue has fluctuated—peaking at $15.2 million in Q2 2026 before settling at $13.55 million this quarter—the company maintains a strong market position within the medical care facilities industry. Management has reaffirmed its full-year Adjusted EBITDA guidance of $12.5 million to $13.5 million, according to reports from GuruFocus.
Down 9.6% since our story on 6 Nov: $7.37 when we broke it → $6.66 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $7.27 |
|---|---|
| 20 Oct | $7.19 |
| 21 Oct | $7.17 |
| 22 Oct | $7.37 |
| 23 Oct | $7.21 |
| 26 Oct | $7.28 |
| 27 Oct | $7.21 |
| 28 Oct | $7.26 |
| 29 Oct | $7.36 |
| 30 Oct | $7.03 |
| 2 Nov | $7.32 |
| 3 Nov | $7.20 |
| 4 Nov | $7.51 |
| 5 Nov | $7.37 |
| 6 Nov | $6.85 |
| 9 Nov | $6.65 |
| 10 Nov | $6.83 |
| 11 Nov | $6.80 |
| 12 Nov | $6.69 |
| 13 Nov | $6.94 |
| 16 Nov | $6.66 |
Industry Landscape
The chiropractic sector continues to benefit from an aging population and a growing preference for non-opioid pain management solutions. However, the industry faces persistent macroeconomic volatility and rising labor costs for skilled healthcare professionals. Peers in the specialized wellness and outpatient facility space have also encountered fluctuating demand as consumer discretionary spending remains under pressure. The Joint’s move to refranchise aligns with broader industry trends where healthcare operators seek to offload the capital intensity of physical locations to third-party owners, focusing instead on high-margin brand management and system-wide technology integration.
| Date | Announcement | Amount |
|---|---|---|
| 05 Nov 2026 | Q3 2026 financial resultsSource: globenewswire.com | $13.6 Million |
| 06 Aug 2026 | Q2 2026 financial resultsSource: ir.thejoint.com | $15.2 Million |
| 07 May 2026 | Q1 2026 financial resultsSource: ir.thejoint.com | $14.8 Million |
| 12 Mar 2026 | Q4 2025 financial resultsSource: ir.thejoint.com | $15.2 Million |
| 06 Nov 2025 | Q3 2025 financial resultsSource: ir.thejoint.com | $13.4 Million |
| 07 Aug 2025 | Q2 2025 financial resultsSource: ir.thejoint.com | $13.3 Million |
| Share price | $7.37 |
|---|---|
| Market cap | $101M |
| Revenue (annual) | $55M |
| P/E (TTM) | 52.6× |
| 1-month price change | +3.66% |
| Sector | HealthcareMedical Care Facilities |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by The Joint Corp. announcing its financial results for the quarter ended September 30, 2026.
Track JOINT Corp live
Get the next JOINT Corp SEC filing seconds after it lands.



